Pharmalittle: glaxo and pfizer will combine otc businesses; allergan recalls breast implants in europe

Hello, everyone, and how are you this fine, sunny morning? The middle of the week has arrived, as you may know, so why not celebrate with a delicious cup of stimulation? After all, you made

is this far, which is a likely sign of surviving another few days. And of course, no prescription is required, which is a good thing. And while you drink up, you can peruse some of the

tidbits we have assembled to help you start the day. Hope you conquer the world and, as always, do keep in touch … GLAXOSMITHKLINE (GSK) AND PFIZER (PFE) PLAN TO COMBINE THEIR CONSUMER

HEALTH-CARE UNITS AND EVENTUALLY SPIN OFF THE JOINT VENTURE, CREATING THE WORLD’S LARGEST SELLER OF DRUGSTORE STAPLES LIKE ADVIL AND SENSODYNE TOOTHPASTE, The Wall Street Journal writes.

It’s an unexpected conclusion to a year-long process by Pfizer to shed its consumer business, as it and other pharmaceutical companies focus more on higher-margin prescription drugs. Glaxo

has been pursuing the same focus, though has until now stayed committed to its consumer business. A CONGRESSIONAL REPORT FOUND THE DRUG ENFORCEMENT ADMINISTRATION AND WHOLESALERS FAILED TO

STOP THE FLOW OF MILLIONS OF OPIOIDS INTO RURAL WEST VIRGINIA DESPITE RAMPANT WARNING SIGNS THE PILLS WERE BEING DIVERTED FOR ABUSE, The Washington Post writes. The House Energy and Commerce

Committee found that distributors failed to conduct proper oversight of their customers by not questioning suspicious activity and not properly monitoring the quantity of painkillers that

were being shipped to individual pharmacies. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS IN-DEPTH

ANALYSIS, NEWSLETTERS, PREMIUM EVENTS, AND NEWS ALERTS. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+.

Subscribe